DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

Milestone Pharmaceuticals ( $MIST ) — from approval to execution

The key change since the December 2025 approval is simple: the stock is no longer being judged mainly on whether CARDAMYST can reach the market, but on whether Milestone can actually turn that approval into real access, real prescriptions, real repeat physician behavior, and eventually a broader etripamil franchise beyond PSVT. That sounds less dramatic than a PDUFA setup, but it is usually the more important phase. Approval can rerate a story for a week. Commercial traction is what can rerate it for much longer.

ImmunityBio (IBRX): from the FDA advertising warning to the company’s fix plan, lawsuit noise, and stronger early Q1 revenue

IBRX APRIL

This update picks up the story where the earlier Merlintrader pieces left it: global expansion, label-expansion ambition and clinical momentum were still moving forward, but the market narrative suddenly shifted when the FDA’s Office of Prescription Drug Promotion publicly challenged how ANKTIVA had been promoted. The key question now is not whether the issue existed — it did — but whether the company’s remediation plan is enough to contain the damage while the underlying commercial story keeps improving.

UiPath ( $PATH ): from classic RPA leader to agentic automation platform

This deep dive looks at where UiPath stands now after fiscal 2026 results, the strategic shift toward agentic automation, the current balance between improving profitability and still-moderate growth, the state of the balance sheet and buyback, the role of Daniel Dines and governance, what institutions and analysts are likely watching, how retail sentiment is split, and what a realistic bull and bear framework looks like from here.

PMGC Holdings (NASDAQ: $ELAB) — update deep dive April 2026

ELAB is no longer just a tiny “obesity + AI + low float” story. Since the prior Merlintrader article, the company has added another manufacturing asset, widened the NorthStrive pipeline, opened a new defense-tech lane, and fully tapped a $20 million Streeterville facility. That gives it more operational breadth, but it also hardens the core problem: cash is less immediate, dilution is more real, and execution now has to work across biotech, industrial integration and defense optionality at the same time.

Applied Digital (APLD) — Deep Dive April 2026

Applied Digital is one of the more interesting infrastructure stories in the market because it sits at the intersection of three forces that investors have spent the last year chasing aggressively: hyperscaler demand, power scarcity, and the belief that the economic winners of the AI cycle will not only be the model builders but also the owners of the physical capacity that makes those workloads possible. That is the seductive version of the story, and it is easy to understand why it caught such a bid.

Cue Biopharma ( $CUE ) — updated deep dive after the CUE-401 push, CEO transition, and fresh Boehringer milestone

Cue Biopharma is trying to turn a once messy, multi-angle small-cap biotech story into a more focused autoimmune thesis. The company now has a clearer lead asset in CUE-401, a meaningful external validation point through CUE-501 and Boehringer Ingelheim, a recent CEO transition, and a balance sheet that is improved versus the most stressed phase of 2025 but still fragile enough that financing risk cannot be pushed into the background.

Lexicon Pharmaceuticals ( $LXRX ): can Zynquista come back?

A full bilingual deep dive built around the real moving parts of the Lexicon story in April 2026: the Zynquista resubmission path after the 2024 complete response letter, the mid-2026 enrollment target for SONATA-HCM, the cash and dilution picture after the January-February 2026 financing, the economics of the Novo Nordisk LX9851 deal, and the structural risks that still make this name a high-volatility small-cap biotech setup.

Adagio Medical Holdings( $ADGM ) Deep Dive April 2026

Adagio Medical is a very small-cap, pre-commercial medtech name trying to carve out a meaningful niche in ventricular tachycardia ablation with its proprietary ultra-low temperature cryoablation platform. What makes the story relevant now is not revenue momentum, because there really is not much of that yet, but the combination of a pivotal study that has already completed enrollment, encouraging acute data, and a fresh FDA IDE expansion that lets the company clinically evaluate its next-generation ventricular catheter while the broader regulatory path remains open.

Aehr Test Systems ( $AEHR ): deep dive on AI burn-in momentum, silicon photonics growth, and the hard execution test still ahead

Revenue fell 44% year over year to $10.3M, while non-GAAP EPS came in at a loss of $0.05. At the same time, quarterly bookings surged to $37.2M and effective backlog reached a record $50.9M. Management also said full-year FY26 revenue should land on the high side of the previously guided $45M-$50M range, while second-half bookings should come in at the high end of the prior $60M-$80M range.

Outlook Therapeutics ( $OTLK ) after the new FDA dispute-resolution meeting. What this April review is.

After three Complete Response Letters and a long fight over what counts as sufficient evidence for ONS-5010 / LYTENAVA in wet AMD, Outlook Therapeutics has now moved into a formal FDA dispute-resolution process. This article walks through the CRL history, the new April 2026 meeting, and the real powers of the FDA deciding official — without hype, but also without pretending the door is already shut.

From Artemis to the Battlefield: why $LUNR, $FLY, $SIDU, $PDYN and $BKSY no longer belong to separate stories

For years, the market framed companies like Intuitive Machines, Firefly, BlackSky, Palladyne AI or Sidus Space as disconnected speculative names orbiting around rockets, satellites or futuristic concepts. That framing is becoming outdated. In 2026, the more useful lens is strategic infrastructure. What matters now is who can move payloads, who can see first, who can process data faster, who can coordinate autonomous systems, and who can fit into the increasingly blurred boundary between civil space, defense tech, sovereign priorities and lunar logistics.

When Good News Is No Longer Enough

There are moments when a positive headline no longer lights a fire under a stock. It opens green, holds for a moment, then fades. That is not always an anomaly. Quite often, it is the market quietly telling you that the story alone is no longer enough.

CorMedix ($CRMD): the real second chapter after commercialization

DefenCath is no longer just a launch story, and CorMedix is no longer easy to reduce to a one-drug binary. The company now has real revenue, positive adjusted EBITDA, a broader anti-infective platform after the Melinta transaction, and an approaching Phase 3 readout for REZZAYO. But it also has one very specific pressure point that still dominates the equity story: the July 1, 2026 reimbursement transition for DefenCath. This report is built to cover every major angle ahead of the ReSPECT topline update and to explain, from first principles, why the reimbursement framework matters so much.

REPL, TVTX, GRCE: three April 2026 PDUFA decisions that matter

A full editorial deep dive on the three most interesting April biotech FDA setups still ahead: Replimune, Travere Therapeutics and Grace Therapeutics. Each story carries a different kind of risk. Replimune is the credibility test after a prior CRL. Travere is the commercial expansion test for a product that already sells. Grace is the classic small-cap binary setup where one approval could change the company’s profile very quickly.